What do systematic reviews say?

Oral hydromorphone vs placebo

The review found no eligible studies for this question.

• Hydromorphone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pregabalin vs placebo

• Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 687 participants
  Very low

Pregabalin vs placebo

• Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1238 participants
  Very low

Paracetamol 500 mg to 650 mg vs placebo

• Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Paracetamol 1000 mg vs placebo

• Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Ketoprofen 25 mg vs placebo

• Ketoprofen for episodic tension‐type headache in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine vs placebo

• Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Oxycodone vs placebo

• Oxycodone for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Azathioprine or 6‐mercaptopurine vs placebo

It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with placebo (very low certainty).

• Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 2.45 [1.22, 4.9]
  4 studies · 556 participants
  Very low

Mycophenolate mofetil vs placebo

• Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Moderate

Type I Interferons vs placebo

Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).

• Type I interferons for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.74 [0.13, 4.14]
  4 studies · 468 participants
  Low

Topical NSAIDs vs topical placebo

• Topical NSAIDs for acute musculoskeletal pain in adults 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Budesonide MMX® 6 mg vs placebo

Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.63 [0.21, 1.91]
  2 studies · 512 participants
  Low

Budesonide MMX® 9 mg vs placebo

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.88 [0.33, 2.4]
  2 studies · 513 participants
  Low

Intermittent LTRA vs placebo

The review found no eligible studies for this question.

• Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Maintenance LTRA vs placebo

The review found no eligible studies for this question.

• Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Etrolizumab vs placebo

Etrolizumab showed no clear difference in serious adverse events compared with placebo (low certainty).

• Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.92 [0.36, 2.34]
  2 studies · 165 participants
  Low

Sulfasalazine vs placebo

Sulfasalazine showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Sulfasalazine for ankylosing spondylitis 2014 · Cochrane Headline outcomes only
  OR 7.5 [0.15, 378.16]
  1 study · 264 participants
  Moderate

Chinese herbal medicines vs placebo

• Chinese herbal medicines for treating osteoporosis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Allopurinol vs placebo

Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  RR 1.93 [0.48, 7.8]
  2 studies · 453 participants
  Moderate